Fariborz Rezai, MD, FCCP FCCM, Rutgers New Jersey Medical School

Gerald Sacks, MD, and Fariborz Rezai, MD, FCCP FCCM, discuss unmet needs and the future treatment landscape in managing opioid-induced constipation.

Fariborz Rezai, MD, FCCP FCCM, comments on the importance of being proactive in addressing opioid-induced constipation early on with patients and shares advice for providers.

Gerald Sacks, MD, and Fariborz Rezai, MD, FCCP, FCCM, share their personal experience in approaching and openly communicating the management of opioid-induced constipation with patients.

The role of lifestyle modifications and over-the-counter products to prevent opioid-induced constipation in patients is discussed.

Gerald Sacks, MD, and Fariborz Rezai, MD, FCCP FCCM, share their approach to selecting PAMORAs in clinical practice for the optimal management of opioid-induced constipation.

A discussion on the use of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic non-cancer pain and the implications for clinical practice.

Gerald Sacks, MD, and Fariborz Rezai, MD, FCCP FCCM, review the diagnosis of opioid-induced constipation and goals of treatment.

Gerald Sacks, MD, discusses the pathophysiology of opioid-induced constipation (OIC) and provides insight on common medical conditions that often lead to OIC.